A Multi-center, Single-dose, Open-label, Parallel Design, Pharmacokinetics Study of BGM0504 Injection in Healthy Participants and Participants With Impaired Renal Function
Latest Information Update: 31 Jul 2025
At a glance
- Drugs BGM 0504 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors BrightGene Bio-medical technology
Most Recent Events
- 21 Apr 2025 New trial record